Clinical Trials Browser

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

Fallopian Tube Neoplasms, Ovarian Neoplasms

Ovarian Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Ovarian Neoplasms

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

Ovarian Neoplasms

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Fallopian Tube Neoplasms, Ovarian Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peripheral Nervous System Diseases

Ovarian Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Fallopian Tube Neoplasms, Genital Diseases, Female, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial, Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

Clinical Trials

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

TroFuse-022

TroFuse-021

KEYNOTE-B96

DO-01

RAINFOL-04

GLORIOSA

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

KEYLYNK-001

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

ATALANTE

DUO-O

A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

SELENIUM

MITO16MANGO2b

IMagyn050

BOOST

Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

NItCHE-MITO33

Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

OCEANS

A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer